Pharmaceutical companies are paying big bucks to get their hands on government-issued vouchers that speed up the approval process for new drugs. The vouchers, which are given for free to companies that develop treatments for rare pediatric or tropical diseases, are selling on the secondary market for as much as $350 million, reported the Wall Street Journal.
The “priority review vouchers” reduce the Food and Drug Administration’s decision deadline to six months from the usual 10 months, which means drug companies gain an extra four months of sales.
Help employers find you! Check out all the jobs and post your resume.
